X
Results

logo

“Please note that this web site is not aimed at consumers as the information herein
contained does not make reference to finished products”.

Search
       
EVIDENCES OF A NEW LECITHIN DELIVERY SYSTEM OF BOSWELLIA SERRATA EXTRACT

Indena to present new studies on Casperome®, its Boswellia serrata extract formulated with the Phytosome® technology.

Casperome_2015

Milan, April 13th, 2015 – Today, at the Pharma-Nutrition Conference in Philadelphia, Christian Artaria, Marketing Director of Indena, will make an oral presentation in a plenary session on the outcomes of a recent pharmacokinetic study on Casperome®, the Boswellia serrata extract formulated with the Indena proprietary Phytosome® technology.

Boswellic acids have long been considered the main bioactive components of Boswellia serrata, and many pre-clinical studies have confirmed their bioactivities. In particular, recent mechanistic studies have validated the capacity of the β-boswellic acid family to modulate physiological response to various challenges, but preliminary pharmacokinetic studies in animals and humans have highlighted the poor oral absorption of boswellic acids[1].

To overcome this problem, Indena has formulated a purified mixture of boswellic acids from Boswellia serrata with lecithin, taking advantage of its proprietary Phytosome® technology platform to optimize their absorption. In a previous pre-clinical work such superior absorption was demonstrated both at the plasma and at the tissue level [2].

The randomized, double blind, cross-over comparative pharmacokinetic study in healthy volunteers with a single oral dosage of 500 mg confirmed a marked increase of major boswellic acids in comparison with the unformulated extract[3]. Plasma levels of most relevant boswellic acids measured after Casperome® administration, in particular β-boswellic acids, were in the range of expected biological activity, thus representing strong support for a rational dosage regimen in clinical testing.

Clinical investigations in four controlled studies have given further support to the relevance of this pharmacokinetic study.

Christian Artaria, Marketing Director of Indena, commented: “We are excited for the results we achieved, as for the first time, with a single dosage of 500 mg of Casperome®, relevant plasmatic levels could be reached and measured in humans”.

 

[1]Du Z. et al. Planta Medica (2015) Feb 25 (under publication)
[2]Hüsch J. et al. Fitoterapia 84 (2013) 89-98
[3]Indena, manuscript submitted for publication

 

*** ***

On Casperome®

Casperome® is a purified mixture of triterpenoid acids from the gum resin of Boswellia serrata. Given the poor bioavailability of these compounds, Indena has formulated the extract with Phytosome® technology to optimize their absorption and further support their functions in modulating physiological response to various challenges.

Further info on Casperome® and other Phytosome®s: www.phytosome.info

Want to know more about Phytosome® technology? Watch the video Phytosome®:The technology explained on the Indena YouTube channel

Follow us on Twitter@IndenaSpA
Follow us on LinkedInhttps://www.linkedin.com/company/indena

Indena Press Contacts
Cohn & Wolfe Milan
Laura Faravelli        laura.faravelli@cohnwolfe.com
Lorenzo Petracco    lorenzo.petracco@cohnwolfe.com
Tel.+39 02 202391

Please note this website is accessible from various countries all over the world and hence it may contain statements or product classification not applicable to your country. The claims made are in reference to ingredients only, hence they do not refer to finished products and they may not comply with Regulation 1924/2006/CE.The marketer of any finished product containing any ingredient is responsible for assuring that the destination of the product and the claims made for the finished product are lawful and comply with all applicable laws and regulations of the country or countries in which the product is to be sold.



Terms & Conditions | Privacy Notice | Copyright©2016 Indena S.p.A. All right reserved Indena S.p.A. tel. +3902574961 fax +390257404620 P.IVA 04411780150